10 drug pricing and market access experts

Experience: Head of Regional Market Access (International) · Amicus Therapeutics

Head of Regional Market Access (International) at Amicus Therapeutics since January 2024; Alasdair also held Senior Director Market Access International (2020–2024) and Director Market Access International (2018–2020) roles at Amicus. The profile cites over 50 successful HTA submissions across multiple rare disease launches and pricing, reimbursement and payer negotiations across EMA markets, Canada and Japan.

Experience: Director, Global Pricing & Access Strategy Lead - Thoracic, HNSCC, Melanoma, Breast, GI GU · Bristol Myers Squibb

Director, Global Pricing & Access Strategy Lead - Thoracic, HNSCC, Melanoma, Breast, GI GU at Bristol Myers Squibb since April 2024, after Associate Director, WW Market Access Strategy Lead (2022–2024) at BMS. Alison's profile describes shaping payer, HTA and evidence strategies for complex oncology portfolios across the U.S. and EU, and the headline cites HTA strategy and global launches.

Experience: Director Global Market Access & Pricing, Oncology · Merck

Former Director Global Market Access & Pricing, Oncology at Merck (2024–2026), where the profile describes serving as franchise pricing lead for KEYTRUDA and new products; Daniel has been Director Global Market Access & Pricing, Vaccines - HPV at Merck since March 2026. Daniel was earlier Director Market Access and Pricing - Oncology at MSD (2021–2024) and Associate Director Market Access at Merck (2018–2021).

Experience: Global Oncology Market Access and Pricing Director · Merck

Global Oncology Market Access and Pricing Director at Merck since May 2024, where the profile describes leading access and pricing strategy for oncology assets (ADC, TCE) and shaping trial design, value story and indication expansion strategy. Isabelle previously held Novartis roles including Global Market Access Lead, Oncology (2019–2022) and Global Patient Access & HEOR Director, Immunology (2015–2019).

Experience: Senior Director, Global Access Strategy and Pricing, Oncology · Pfizer

Senior Director, Global Access Strategy and Pricing, Oncology at Pfizer since August 2025, leading access strategy across US and international markets for an antibody-drug conjugate therapy being explored in lung cancer and other solid tumors, per the profile. James was previously Global Access Strategy & Pricing Director, Hematology-Oncology (2019–2025), a role the profile describes as managing access strategy and pricing, and Market Access Manager (2015–2019) at Pfizer.

Experience: Global Access Strategy & Pricing Oncology Pipeline & BD · Pfizer

Global Access Strategy & Pricing Oncology Pipeline & BD at Pfizer since June 2025, after team lead roles in Global Access Strategy & Pricing for the Specialty Care Pipeline & BD (2024–2025) and the Atopic Dermatitis Franchise (2022–2024). Joanna was earlier Sr Director Global Market Access, Inflammation & Immunology (2020–2022) and Director, Global Market Access Oncology (2015–2020) at Pfizer; the profile says Joanna led the global launches of 5 medicines.

Experience: Senior Director, Global Market Access & Pricing, Oncology · Daiichi Sankyo

Senior Director, Global Market Access & Pricing, Oncology at Daiichi Sankyo since April 2019. Khalid's profile describes a strategic leader in market access, pricing and reimbursement with knowledge of US and global healthcare systems across the EU, Asia-Pacific and Latin America, and experience across pipeline and in-line products in oncology, immuno-oncology, specialty and primary care.

Experience: Global Pricing and Market Access Director · GSK

Global Pricing and Market Access Director at GSK since 2019, where the profile describes leading payer activities for the respiratory franchise, developing and implementing pricing strategy and leading market access go/no-go launch decisions. Lois earlier held director roles covering pricing, market access, reimbursement or value access at Kyowa Pharmaceutical (interim, 2017–2018), Amgen (2016–2017), Teva Pharmaceuticals (interim, 2016) and Reckitt (2014–2015).

Experience: Global Market Access and Pricing Director · Sanofi

Global Market Access and Pricing Director at Sanofi since 2022, with global responsibility, per the profile, for optimising international access and pricing in gastroenterology and leading the development and execution of the gastro access and pricing strategy. Matthew was previously Senior Value and Access Manager (2019–2022) and Cardiovascular Value and Access Manager (2018–2019) at Sanofi.

Experience: Director Global Access Strategy & Pricing Oncology · Pfizer

Former Director Global Access Strategy & Pricing Oncology at Pfizer (2024–2026) and Director Value Access and Pricing International at Seagen (2021–2023); Yves has been Director and Head Market Access & Reimbursement International at Abbott since May 2026. The profile cites 15+ years delivering HTA, pricing and reimbursement outcomes, developing global pricing strategies, driving AMNOG negotiations and leading early payer engagements.